WO1994010313A3 - Interferon tau compositions and methods of use - Google Patents

Interferon tau compositions and methods of use Download PDF

Info

Publication number
WO1994010313A3
WO1994010313A3 PCT/US1993/010016 US9310016W WO9410313A3 WO 1994010313 A3 WO1994010313 A3 WO 1994010313A3 US 9310016 W US9310016 W US 9310016W WO 9410313 A3 WO9410313 A3 WO 9410313A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
proteins
interferon
interferon tau
compositions
Prior art date
Application number
PCT/US1993/010016
Other languages
French (fr)
Other versions
WO1994010313A2 (en
Inventor
Fuller Warren Bazer
Howard Marcellus Johnson
Carol Hanlon Pontzer
Troy Lee Ott
Heeke Gino Van
Kazuhiko Imakawa
Original Assignee
Univ Florida
Women S Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Women S Research Inst filed Critical Univ Florida
Priority to EP93924958A priority Critical patent/EP0669981A1/en
Priority to AU54449/94A priority patent/AU689450B2/en
Priority to CA002148119A priority patent/CA2148119A1/en
Priority to JP6511137A priority patent/JPH08505047A/en
Publication of WO1994010313A2 publication Critical patent/WO1994010313A2/en
Publication of WO1994010313A3 publication Critical patent/WO1994010313A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention describes the production of interferon-τ proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-τ protein are also described.
PCT/US1993/010016 1992-10-30 1993-10-19 Interferon tau compositions and methods of use WO1994010313A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP93924958A EP0669981A1 (en) 1992-10-30 1993-10-19 Interferon tau compositions and methods of use
AU54449/94A AU689450B2 (en) 1992-10-30 1993-10-19 Interferon tau compositions and methods of use
CA002148119A CA2148119A1 (en) 1992-10-30 1993-10-19 Interferon tau compositions and methods of use
JP6511137A JPH08505047A (en) 1992-10-30 1993-10-19 Interferon tau compositions and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96989092A 1992-10-30 1992-10-30
US07/969,890 1992-10-30

Publications (2)

Publication Number Publication Date
WO1994010313A2 WO1994010313A2 (en) 1994-05-11
WO1994010313A3 true WO1994010313A3 (en) 1994-10-27

Family

ID=25516125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/010016 WO1994010313A2 (en) 1992-10-30 1993-10-19 Interferon tau compositions and methods of use

Country Status (8)

Country Link
EP (2) EP1360962A3 (en)
JP (1) JPH08505047A (en)
KR (1) KR100357768B1 (en)
CN (1) CN1090510A (en)
AU (1) AU689450B2 (en)
CA (1) CA2148119A1 (en)
TW (2) TW585911B (en)
WO (1) WO1994010313A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
KR100464531B1 (en) * 1996-04-12 2005-03-07 유니버시티 오브 플로리다 Hybrid interferon compositions and methods of use
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
FI104363B (en) * 1997-05-19 2000-01-14 Timo Kalevi Korpela Enhancement of the pharmacological interaction of immunosuppressants and interferons with additives
EP1156771A2 (en) * 1999-06-22 2001-11-28 The University Of Maryland Interferon tau mutants and methods for making them
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
WO2001016178A1 (en) * 1999-08-27 2001-03-08 University Of Florida MATERIALS AND METHODS FOR INHIBITION OF IgE PRODUCTION
EP1355938A2 (en) * 2000-07-19 2003-10-29 Pepgen Corporation Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
US7105154B2 (en) * 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
JP2006213597A (en) 2000-07-19 2006-08-17 Pepgen Corp Composition for treating hepatitis c virus by using interferon tau and method of monitoring
US7083782B2 (en) 2000-07-19 2006-08-01 Pepgen Corporation Method of treatment using interferon-tau
US7431920B2 (en) 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US7232563B2 (en) 2001-08-12 2007-06-19 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
TW200518768A (en) * 2003-11-17 2005-06-16 Pepgen Corp Methods for treatment of obesity and for promotion of weight loss
WO2007018846A2 (en) * 2005-07-27 2007-02-15 Pepgen Coporation Use of interferon- tau for reduction of scar tissue formation
JPWO2007037098A1 (en) 2005-09-27 2009-04-02 株式会社林原生物化学研究所 Reproductive disorder improving agent
US20090035273A1 (en) * 2006-08-18 2009-02-05 Pepgen Corporation Combination treatment method with interferon-tau
CN101244261B (en) * 2008-03-10 2010-09-15 山东大学 Biological agent containing non-renaturation recombinant protein, preparation method and application thereof
CN113969285B (en) * 2021-11-09 2023-05-23 上海市农业科学院 Recombinant expressed sheep interferon-tau BB8 gene and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367063A1 (en) * 1988-10-26 1990-05-09 The Curators Of The University Of Missouri Isolation and cloning of complementary DNA for gene coding of bovine trophoblast protein-1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638207B2 (en) * 1988-03-18 1993-06-24 Institut National De La Recherche Agronomique (Inra) Isoforms of trophoblastine
WO1990009806A2 (en) * 1989-03-02 1990-09-07 University Of Florida Composition for the inhibition of tumors and for the non-cytotoxic inhibition of replication of viruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367063A1 (en) * 1988-10-26 1990-05-09 The Curators Of The University Of Missouri Isolation and cloning of complementary DNA for gene coding of bovine trophoblast protein-1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0669981A1 *

Also Published As

Publication number Publication date
EP0669981A1 (en) 1995-09-06
TW391983B (en) 2000-06-01
KR100357768B1 (en) 2003-04-07
EP1360962A2 (en) 2003-11-12
EP1360962A3 (en) 2004-02-04
KR950704489A (en) 1995-11-20
AU689450B2 (en) 1998-04-02
TW585911B (en) 2004-05-01
CN1090510A (en) 1994-08-10
WO1994010313A2 (en) 1994-05-11
CA2148119A1 (en) 1994-05-11
AU5444994A (en) 1994-05-24
JPH08505047A (en) 1996-06-04

Similar Documents

Publication Publication Date Title
WO1994010313A3 (en) Interferon tau compositions and methods of use
AU638982B2 (en) Use of cytokines
IL79085A (en) Hybrid interferons having an amino acid sequence composed of sub-sequences of human lymphoblastoid interferons lyifn-alpha-2 and lyifn-alpha-3,their preparation and pharmaceutical compositions containing them
AU558966B2 (en) Interferon and amino acid as stabilizer
AU2666197A (en) Hybrid interferon compositions and methods of use
CA2178752A1 (en) N-Terminally Chemically Modified Protein Compositions and Methods
AU2535188A (en) Pharmaceutical compositions of recombinant beta-interferon and formulation processes
AU574323B2 (en) Yeast expression of interferon and other proteins
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
ATE156361T1 (en) PROTEIN-CONTAINED MEDICINAL PRODUCTS WITH DELAYED RELEASE
AU2928789A (en) Low ph pharmaceutical compositions of recombinant beta-interferon
IE822385L (en) Recombinant dna's coding for interferon polypeptides
HUT63063A (en) Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same
WO2003016472A3 (en) Hybrid interferon/interferon tau proteins, compositions and methods of use
AU7817387A (en) Purification of recombinant tumor necrosis factor
EP0149551A3 (en) Gamma interferon-interleukin-2 synergistic compositions and processes therefor
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
ZA896980B (en) Peptide compounds
NZ227944A (en) Synergistic pharmaceutical composition of a hybrid interferon and a muramylpeptide
NZ222179A (en) 4,5-dihydro- and 4,5,6,7-tetrahydropyrazolo (1,5-a)pyrimidines and pharmaceutical compositions
NZ229346A (en) Oxadiazolyl-substituted imidazo(1,5-a)quinoxaline derivatives and pharmaceutical compositions
CA2114859A1 (en) Cytotoxic and antiviral compound
NZ219027A (en) Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
EP0254593A3 (en) Preparation and uses of interferon-gamma
AU2596888A (en) Peptide structures, immunogens containing them and their uses in the control of fertility

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2148119

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019950701721

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1993924958

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993924958

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993924958

Country of ref document: EP